Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
146 Depression Trials near New York, NY
Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
This trial is testing the efficacy of an investigational drug, SP-624 (study drug) to see how well it might work to treat major depressive disorder.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
456 Participants Needed
A Phase 2/3 Trial is designed to evaluate SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, PTSD, Others
900 Participants Needed
Lumateperone for Major Depressive Disorder
New York, New YorkThis trial is testing lumateperone, a medication that may help people with depression who haven't improved with other treatments. The study includes patients diagnosed with Major Depressive Disorder who haven't responded well to their current antidepressants. Lumateperone works by balancing brain chemicals that affect mood, potentially improving depressive symptoms.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Anxiety, Others
Must Be Taking:Antidepressants
470 Participants Needed
NMRA-335140 for Depression
New York, New YorkThis is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Personality Disorder, Bipolar, Schizophrenia, Others
332 Participants Needed
NMRA-335140 for Depression
New York, New YorkThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Personality Disorder, Bipolar, Schizophrenia, Others
650 Participants Needed
Psilocybin Analog for Depression
New York, New YorkThe purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
Stay on current meds
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Suicide Risk, Others
Must Be Taking:Antidepressants
220 Participants Needed
Multiple Medications for Bipolar Depression
New York, New YorkThis trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:18 - 75
Sex:All
2726 Participants Needed
AXS-05 for Depression
New York, New YorkThis trial is testing AXS-05, a new medication, to see if it can prevent depression from returning in people who have already improved with it. The study focuses on those with major depressive disorder and aims to maintain their balanced brain chemicals to keep them feeling better. AXS-05 (a combination of dextromethorphan and bupropion) has shown positive results in previous trials for major depressive disorder.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Other AXS-05 Studies, Others
Must Not Be Taking:Auvelity
350 Participants Needed
Cariprazine for Bipolar Disorder
New York, New YorkThis trial will use cariprazine (Vraylar) to treat individuals with bipolar depression who are not currently on medication. Researchers will use brain scans to understand how the medication affects the brain. The goal is to improve treatment options for those who do not respond well to current medications.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:18 - 60
Sex:All
8 Participants Needed
Psilocybin + Pimavanserin for Depression
New York, New YorkThis is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of psilocybin. Evaluations will be taken before dosing and following dosing at several timepoints up to 5 weeks post-dosing.
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Psychotic Disorder, Severe Depression, Suicidal Ideation, Others
Must Not Be Taking:Antipsychotics, Antidepressants, Mood Stabilizers, Others
60 Participants Needed
Ketamine-Assisted Psychotherapy for Depression
New York, New YorkThis trial compares two treatments for adults with severe depression. One treatment uses ketamine combined with therapy, and the other uses only ketamine. Ketamine helps improve mood by changing brain chemistry, and therapy might make these improvements last longer. Ketamine, originally a dissociative anesthetic, has been increasingly used for treatment-resistant depression due to its rapid antidepressant effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Schizophrenia, Bipolar, Others
Must Be Taking:Antidepressants
70 Participants Needed
BI 1569912 for Depression
New York, New YorkThis study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
Participants are put into 4 groups randomly, which means by chance. Three of the 4 groups take different doses of BI 1569912 and 1 group takes placebo. Placebo tablets looks like BI 1569912 but do not contain any medicine. Participants take the tablets once a day for 6 weeks.
Participants are in the study for about 2.5 months. During this time, they visit the study site at least 7 times. At the visits, doctors and their staff ask participants about their depression symptoms. At the end of the study, the results are compared between the groups to see whether the treatment works. The doctors also regularly check the general health of participants and take note of any unwanted effects.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Seizure Disorders, Others
224 Participants Needed
SGLT2 Inhibitor for Depression
New York, New YorkThis trial is testing whether empagliflozin, a medication that helps produce ketone bodies, can reduce depression symptoms. It targets people with depression by providing an alternative energy source for the brain, potentially improving their mood.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Substance Use, Others
Must Not Be Taking:Psychotropics, SGLT2 Inhibitors
16 Participants Needed
Digital Intervention + Cognitive Strategies for Post-Stroke Depression
New York, New YorkThis trial tests a new treatment for stroke patients with depression and thinking problems. The treatment uses an iPad app to train the brain and online coaching to teach new thinking strategies. It aims to improve mood, thinking skills, and daily functioning.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 79
Sex:All
Key Eligibility Criteria
Disqualifiers:Receptive Aphasia, Dementia, Psychosis, Others
Must Be Taking:Antidepressants
70 Participants Needed
ABX-002 for Bipolar Depression
New York, New YorkThe goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment shows effects on brain chemistry that may relate to anti depressive effects
This is a single treatment arm, open-label, Phase 2 study of ABX-002 in 30 adults with bipolar disorder and 5 healthy volunteers. Healthy volunteer participants will receive no drug treatment and will undergo 2 imaging sessions to confirm instrument and test - retest method reliability control. For bipolar disorder participants with depression, the study will include 3 study periods:
1. Screening Period of up to 4 weeks
2. 6-week Treatment Period
3. 2-week post dose Safety Follow-up Period.
For healthy volunteers, the study will include 2 study periods:
1. Screening Period of up to 3 weeks
2. Imaging Period of up to 3 weeks.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Rapid Cycler, Schizophrenia, OCD, Others
Must Be Taking:Mood Stabilizers, Atypical Antipsychotics
35 Participants Needed
BHV-7000 for Depression
New York, New YorkThis trial is testing a new medication called BHV-7000 to see if it is safe and well-tolerated over several months in people with Major Depressive Disorder. The goal is to help those who suffer from severe depression by potentially offering a new treatment option.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:18 - 75
Sex:All
480 Participants Needed
Centanafadine for Depression
New York, New YorkThis is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).
The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
336 Participants Needed
Pramipexole for Anxiety and Depression
New York City, New YorkThis trial tests if pramipexole can help adults with anxiety or depression feel more socially connected. Pramipexole increases dopamine levels in the brain, which may improve how people respond to positive social interactions. The study will measure brain activity, behavior, and self-reported feelings before and after a period of treatment. Pramipexole has shown potential to improve mood and reduce anxiety in both experimental and clinical settings.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Suicide Risk, Bipolar, Psychotic Disorders, Others
Must Not Be Taking:SSRIs, Benzodiazepines, Others
108 Participants Needed
Accelerated TMS for Depression and OCD
New York, New YorkThis trial tests a new, faster treatment for people with depression and OCD. The goal is to see if this approach can quickly improve symptoms. The study also uses brain scans to find markers that predict who will benefit most from the treatment. This method has shown effectiveness in treating depression and cognitive impairment, and is being explored for its potential in treating OCD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Suicide Risk, Substance Use Disorder, Neurological Disorder, Others
500 Participants Needed
Mental Health App + Remote Therapy for Depression
New York, New YorkThis study will investigate whether an intervention that includes remotely delivered therapy sessions and a digital mental health app, compared to only remotely delivered therapy reduces late-life depression
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:50 - 80
Sex:All
60 Participants Needed
Kandoo App for Depression
New York, New YorkThe current project is a pilot study that seeks to compare the efficacy of Brief Behavioral Activation's treatment-as-usual that uses paper and pencil tools to Kandoo, a digital, gamified version of activity scheduling and self-monitoring, in a diverse sample of youth presenting with clinically significant symptoms of depression. We will compare the level of pre- and post-treatment depressive symptoms in participants, who will participate in an 8-week brief behavioral activation treatment protocol augmented with Kandoo to the pre- and post- treatment depressive symptoms in the control participants, who will participate in 8-week, treatment as usual, brief behavioral activation treatment protocol. To explore treatment response for the clinically significant symptoms, we will obtain pre- and post-treatment measures of depression, global functioning, and patient goals. During the standard clinical intake, additional information will be obtained, including detailed demographics, medical history, mental health status, and social skills. Beyond determining the overall effectiveness of BBA augmented with Kandoo, the sample diversity and availability of clinical behavioral observations of the participants will permit the development of explanatory models of predictive factors for BBA with Kandoo intervention outcomes.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:13 - 25
Sex:All
200 Participants Needed
Deep TMS for Depression
Brooklyn, New YorkThis trial is testing a device that uses magnetic pulses to stimulate the brain. It aims to help people with Major Depressive Disorder who have depressive episodes. The study will check if this new method is as safe and effective as current treatments. Magnetic seizure therapy (MST) is a potential alternative to electroconvulsive therapy (ECT) that may not adversely affect memory.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22 - 68
Sex:All
Key Eligibility Criteria
Disqualifiers:Substance Abuse, Psychotic Disorders, Bipolar, Others
Must Not Be Taking:Investigational Drugs
104 Participants Needed
Tele-PROTECT Therapy for Depression
New York, New YorkThis trial tests a video-based therapy called Tele-PROTECT for older adults in NYC who have been abused and are depressed. The therapy helps participants feel better by engaging them in enjoyable activities and setting safety goals. The aim is to see if this approach reduces depression and increases safety.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Sex:All
Key Eligibility Criteria
Disqualifiers:Suicidal Ideation, Language Barrier, Others
140 Participants Needed
Social Reward Psychotherapy for Suicidal Thoughts
New York, New YorkThis trial tests a new talk therapy called Engage & Connect, aimed at middle-aged and older adults who feel socially isolated. The therapy encourages enjoyable social activities to help improve mood and reduce suicidal thoughts by making people feel happier and more connected.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Severe Medical Illness, Others
Must Be Taking:Antidepressants
128 Participants Needed
Mobile CBT for Anxiety and Depression
New York, New YorkThis trial tests a mobile app called MAYA that helps middle-aged and older adults with anxiety or depression. The app teaches coping skills from cognitive behavioral therapy. Participants will use the app regularly over several weeks. The study aims to see if the app is easy to use and effective in reducing symptoms.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:40+
Sex:All
60 Participants Needed
Transcranial Photobiomodulation for Depression
New York, New YorkThis trial is testing a special kind of invisible light aimed at the forehead to help people with depression. The light might improve blood flow in the brain. About 60 people with depression will be part of this study to see if this treatment works.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar, Substance Use, Neurological, Others
Must Be Taking:SSRIs, SNRIs, Wellbutrin
120 Participants Needed
Brain Stimulation for Depression
New York, New YorkThis trial uses electrical stimulation in specific brain areas to help manage symptoms of major depressive disorder in people who also have epilepsy. By monitoring and stimulating certain brain regions, researchers aim to adjust brain activity to improve mood and decision-making.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Over 80, Under 18
10 Participants Needed
Community-based Psychological Services for Mental Health
New York, New YorkThis trial aims to improve mental health and COVID-19 prevention behaviors among minority and vulnerable groups in New York City by training community workers to provide basic mental health support using Problem Management Plus (PM+).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Acute Suicide Risk, Others
1000 Participants Needed
Combined Therapies for Maternal PTSD
New York, New YorkThis trial tests a program that helps mothers with PTSD learn to manage their emotions and improve their interactions with their children. It aims to reduce stress and improve family dynamics for mothers receiving family preservation services.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 64
Sex:Female
Key Eligibility Criteria
Disqualifiers:Suicidal Ideation, Severe Substance Use, Psychosis, Others
160 Participants Needed
Deep Brain Stimulation for Treatment-Resistant Depression
New York, New YorkThis trial is testing a new device that sends electrical signals to the brain to help people with severe depression who don't respond to usual treatments. The device also records brain activity to understand how the treatment works. The study will involve 10 patients and last for several years. Deep brain stimulation (DBS) has been investigated for a long time as a treatment for severe, treatment-resistant depression, showing potential but requiring further research.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:25 - 70
Sex:All
10 Participants Needed
Page 1 of 5+
Frequently Asked Questions
How much do Depression clinical trials in New York, NY pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Depression clinical trials in New York, NY work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Depression trials in New York, NY 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in New York, NY for Depression is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in New York, NY several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Depression medical study in New York, NY ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Depression clinical trials in New York, NY ?
Most recently, we added Mental Health App + Remote Therapy for Depression, Morphine or Ketamine for Pain and Clinical Decision Support Tool for Postpartum Depression to the Power online platform.
What do the "Power Preferred" and "SuperSite" badges mean?
We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.
Which clinics have received Power Preferred and SuperSite awards recruiting for Depression trials in New York, NY ?
The Depression clinics in New York, NY currently recognized as SuperSites are: Integrative Clinical Trials in Brooklyn, New York Integrative Clinical Trials in Brooklyn, New York